<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631501</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx180.001</article-id><article-id pub-id-type="publisher-id">ofx180.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Late Breaker Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Cap-dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza: Results from a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study in Otherwise Healthy Adolescents and Adults with Seasonal Influenza</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Portsmouth</surname><given-names>Simon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Kawaguchi</surname><given-names>Keiko</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Arai</surname><given-names>Masatsugu</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Tsuchiya</surname><given-names>Kenji</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Uehara</surname><given-names>Takeki</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Shionogi Inc.</institution>, <addr-line>Florham Park, New Jersey;</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Shionogi &#x00026; Co., Ltd.</institution>, <addr-line>Osaka</addr-line>, <country>Japan</country>;</aff><aff id="AF0003">
<label>3</label>
<institution>Shionogi &#x00026; Co Ltd.</institution>, <addr-line>Osaka</addr-line>, <country>Japan</country></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 228. Late Breaker Oral Abstracts</p><p>
<italic>Saturday, October 7, 2017: 10:30 AM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S734</fpage><lpage>S734</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx180.001.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Cap-dependent endonuclease (CEN) resides in the PA subunit of influenza virus polymerase and mediates the &#x0201c;cap-snatching&#x0201d; process during viral mRNA biosynthesis. S-033188 is a potent, selective, small molecule inhibitor of CEN. Here we report clinical and virologic outcomes from a global Phase 3 study CAPSTONE-1.</p></sec><sec id="s2"><title>Method</title><p>This was a multicenter, randomized, double-blind, placebo- and active-controlled study. Key eligibility criteria included 12&#x02013;64&#x000a0;years of age, fever (axillary temperature &#x02265;38.0&#x000b0;C), &#x02265;1 general symptom and &#x02265;1 respiratory symptom (moderate to severe), and &#x02264;48 hours from symptom onset. Patients between 20 and 64&#x000a0;years of age were randomized in 2:2:1 ratio to receive a single oral administration of S-033188, placebo, or 75&#x000a0;mg oseltamivir BID for 5&#x000a0;days. Patients between 12 and 19&#x000a0;years of age were randomized in 2:1 ratio to receive either a single oral administration of S-033188 or placebo. The primary efficacy endpoint was time to alleviation of influenza symptoms (TTAS) in the infected intent to treat population. Viral titer and RNA content were determined from pre- and postdose nasal/throat&#x000a0;swabs.</p></sec><sec id="s3"><title>Result</title><p>A&#x000a0;total of 1436 patients were randomized. TTAS was significantly shorter in the S-033188 group than that in the placebo group (median TTAS: 53.7 hours vs. 80.2 hours, <italic>P &#x0003c;</italic> 0.0001). Median time to cessation of viral shedding was 24 hours in patients treated with S-033188, compared with 72 hours in those treated with oseltamivir (<italic>P &#x0003c;</italic> 0.0001) and 96 hours for placebo (<italic>P &#x0003c;</italic> 0.0001). Patients in the S-033188 group had significantly greater reductions from baseline in both viral titer and RNA content than those in oseltamivir or placebo groups at all time-points until Day 3 (compared with oseltamivir) or Day 5 (compared with placebo). S-033188 was generally well tolerated, with overall incidence of treatment-emergent adverse events lower than that seen with oseltamivir.</p></sec><sec id="s4"><title>Conclusion</title><p>Treatment with S-033188 was superior to placebo in alleviating influenza symptoms, and superior to both oseltamivir and placebo in virologic outcomes. Safety profile of S-033188 compared favorably with that of oseltamivir.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>S.&#x000a0;Portsmouth</bold>, Shionogi Inc.: Employee, Salary. <bold>K. Kawaguchi</bold>, Shionogi &#x00026; Co., Ltd.: Employee, Salary. <bold>M. Arai</bold>, Shionogi &#x00026; Co Ltd: Employee, Salary. <bold>K. Tsuchiya</bold>, Shionogi &#x00026; Co., Ltd.: Employee, Salary. <bold>T. Uehara</bold>, Shionogi &#x00026; Co., Ltd.: Employee, Salary.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>